Evaluating a digital tool for supporting people affected by breast cancer: a prospective randomized controlled trial—the ADAPT study

• Published in: Supportive care in cancer Vol. 32; no. 11; p. 740
• Main Authors: Vrancken Peeters, Noelle J. M. C., Husson, Olga, Kulakowski, Rafal, Hainsworth, Emma, Lidington, Emma, McGrath, Sophie E., Noble, Jillian, Azarang, Leyla, Cruickshank, Susanne, Georgopoulou, Sofia
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.11.2024; Springer Nature B.V
• Subjects: Adult; Aged; Breast cancer; Breast Neoplasms - psychology; Breast Neoplasms - therapy; Clinical trials; Digital technology; Female; Health Status; Humans; Medicine; Medicine & Public Health; Middle Aged; Nursing; Nursing Research; Oncology; Pain Medicine; Patient Participation - methods; Prospective Studies; Quality of Life; Questionnaires; Rehabilitation Medicine; Self-Management - methods; Surveys and Questionnaires; Patient activation; Supportive care; Breast cancer; Health-related quality of life (HRQoL); Health status; EHealth
• ISSN: 0941-4355; 1433-7339; 1433-7339
• DOI: 10.1007/s00520-024-08923-3

Purpose This study reports the findings from the ADAPT randomized controlled trial (RCT), concerning the impact of a digital tool for supported self-management in people affected by breast cancer on patient activation as the primary outcome, with health-related quality of life (HRQoL), and health status as secondary outcomes. Methods Women with early-stage breast cancer were randomly assigned to standard care (control) or standard care in addition to the breast cancer digital tool (intervention). Data were collected using a demographic questionnaire, the Patient Activation Measure (PAM-13), the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30), and the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) at baseline, 6 weeks, 3 months, 6 months, and 1 year from diagnosis. Linear mixed effect model regression was used to assess the effect of the digital tool over the first year from diagnosis while correcting for intra-participant correlation. Results A total of 166 participants were included, with 85 being randomized into the intervention. No significant differences ( p  > 0.05) in the PAM-13 scores, EORTC QLQ-C30 scales (global QoL, physical functioning, emotional functioning, pain, fatigue), and EQ-5D-5L Index between the control and intervention groups were observed. It is important to note that there was significant non-adherence within the intervention group. Conclusion The breast cancer digital tool had no statistically significant impact on patient activation, HRQoL, and health status over time compared to standard care alone in women with early-stage breast cancer. Future research should focus on identifying and addressing barriers to digital tool engagement to improve efficacy. Clinical trial information The study was registered at https://clinicaltrials.gov (NCT03866655) on 7 March 2019 ( https://clinicaltrials.gov/study/NCT03866655 ).